Effectiveness of the treatment of keloid with fractional carbon dioxide laser monotherapy versus fractional carbon dioxide laser-assisted topical clobetasol ointment

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20251212002

Enrollment

Registered

2025-12-12

Start date

2025-12-02

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Keloid scar on chest Keloid scar Fractional carbondioxide laser Fractional carbon dioxide laser-assisted Clobetasol ointment

Interventions

1. Fractional CO2 laser 2. Petrolatum white apply lesion as placebo,1. Fractional CO2 laser 2. 0.05% clobetasol propionate ointment apply lesion

Placebo Comparator Device,Active Comparator Drug

Fractional CO2 laser with placebo,Fractional CO2 laser with clobetasol ointment

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Can communicate and willing to participate in the study. 2. There is at least 1 keloid scar size 2 - 4 cm. on chest. 3. Sign in informed consent to participate in the study until finish.

Exclusion criteria

Exclusion criteria: 1. Has any severe heart, liver or renal disease. 2. Has any conditions of autoimmune disease, thrombocytopenia, coagulopathy, vitiligo, psoriasis, infection or rash on chest. 3. Taking of isotretinoin within 6 - 12 months before participate in the study. 4. Pregnancy or during lactation or attempt to conceive. 5. History of photo or laser sensitive. 6. History of allergy to medication use in study. 7. History of treatment on keloid scar that attempt to participate in study within 6 months before participate in the study.

Design outcomes

Primary

Measure	Time frame
Vancouver scar score at 20 weeks after end of the intervention Vancouver scar scale,Pliability at 20 weeks after end of the intervention Cutometer,Height at 20 weeks after end of the intervention Antera 3D camera,Height at 20 weeks after end of the intervention Caliper,Adverse events at 20 weeks after end of the intervention Case record form,Patient satisfaction at 20 weeks after end of the intervention Satisfaction scale	—

Measure

Time frame

Vancouver scar score at 20 weeks after end of the intervention Vancouver scar scale,Pliability at 20 weeks after end of the intervention Cutometer,Height at 20 weeks after end of the intervention Antera 3D camera,Height at 20 weeks after end of the intervention Caliper,Adverse events at 20 weeks after end of the intervention Case record form,Patient satisfaction at 20 weeks after end of the intervention Satisfaction scale

—

Secondary

Measure	Time frame
Vancouver scar score at 4, 8, 12, 16 weeks after end of the intervention Vancouver scar scale,Pliability at 4, 8, 12, 16 weeks after end of the intervention Cutometer,Height at 4, 8, 12, 16 weeks after end of the intervention Antera 3D camera,Height at 4, 8, 12, 16 weeks after end of the intervention Caliper,Adverse events at 4, 8, 12, 16 weeks after end of the intervention Case record form,Patient satisfaction at 4, 8, 12, 16 weeks after end of the intervention Satisfaction scale	—

Measure

Time frame

Vancouver scar score at 4, 8, 12, 16 weeks after end of the intervention Vancouver scar scale,Pliability at 4, 8, 12, 16 weeks after end of the intervention Cutometer,Height at 4, 8, 12, 16 weeks after end of the intervention Antera 3D camera,Height at 4, 8, 12, 16 weeks after end of the intervention Caliper,Adverse events at 4, 8, 12, 16 weeks after end of the intervention Case record form,Patient satisfaction at 4, 8, 12, 16 weeks after end of the intervention Satisfaction scale

—

Countries

Thailand

Contacts

Public ContactTippawan Boonseree

Institute of Dermatology

Boonseree@gmail.com023545222

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026